Nektar to change into therapeutics drug development organization

The restructuring is expected to streamline the company, consolidate corporate functions, and strengthen decision-making and execution within the business units. Approximately 150 positions have been eliminated as a result of the restructuring. Importantly, Nektar has preserved the necessary technical and manufacturing personnel and capabilities to support its ongoing effort to forge a new partnership for its inhaled insulin programs.

Howard Robin, president and CEO of Nektar, said: “This restructuring aligns the organization with the future direction of our company and strengthens our ability to drive programs rapidly through the clinic.”